Skip to content

Evaluation of an Early Support Programme in Orthophony

Evaluation of an Early Support Programme in Orthophony : the PAPEV-ortho Study

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04384328
Acronym
PAPEV-ortho
Enrollment
76
Registered
2020-05-12
Start date
2019-11-27
Completion date
2022-12-31
Last updated
2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Language Development Disorders, Preterm Birth

Keywords

language Development, communication Development, preterm infant, orthophony

Brief summary

Prospective, interventionnal with minimal risks and constraints, multicentric, non-randomized, open study, to measure the impact of an early support programme in speech and language therapy for vulnerable children (PAPEV-ortho), in children born very prematurely or very hypotrophically, on the incidence of language and communication deficits at the corrected age of 2 years.

Detailed description

Prospective, interventionnal with minimal risks and constraints, multicentric, non-randomized, open study, to measure the impact of an early support programme in speech and language therapy for vulnerable children (PAPEV-ortho), in children born very prematurely or very hypotrophically, on the incidence of language and communication deficits at the corrected age of 2 years. Parents of eligible children are informed of the study either during the hospitalization of the neonatal newborn by a hospital physician, or during a consultation performed during the first 6 months by a pilot physician from the RPSOF-ASNR network, hospital or private practitioner. Parents who agree that the data collected about their child may be used in the study sign a written declaration of free and informed consent. The Early Support Programme in orthophony (PAPEV-ortho) is systematically proposed to families with possible access to a language therapist in the network. Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools. The support focuses on: * the development of parental sensitivity and receptivity * the development of parental reactivity * optimization of communication sequences in routine acts and play * the development of the child's intentionality in play and routine acts * support for verbal and non-verbal oral communication The participation of the child and his or her parents in the study ends at the end of the consultations and evaluations carried out at 24 months of corrected age. Children within the group that followed the PAPEV-ortho program will be compared to children who did not benefit from this program.

Interventions

OTHEREarly Support Programme in Orthophony

Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.

Sponsors

Centre Hospitalier Sud Francilien
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Prospective, interventionnal with minimal risks and constraints, multicentric, non-randomized, open study.

Eligibility

Sex/Gender
ALL
Age
No minimum to 6 Months
Healthy volunteers
No

Inclusion criteria

* Premature birth \< 32 weeks of amenorrhea * or premature birth with intrauterine growth restriction (IUGR) \< P3 * corrected age ≤ 6 months at the time of inclusion * affiliation to a social security system + mutual insurance

Exclusion criteria

* genetic pathology * ongoing developmental care: psychomotricity or speech therapy * neuromuscular pathology affecting oral and facial motor skills * severe oral disorders: feeding by gastric tube or gastrostomy * severe sensory, auditory or visual impairment * neither of the 2 French-speaking parents

Design outcomes

Primary

MeasureTime frameDescription
Score in the Ages & Stages Questionnaires communication domain at 24 months of corrected age.at 24 months of corrected agePercentage of children with a score of ≤ 45 in the communication domain of the Ages \& Stages Questionnaires questionnaire (from 0=worst to 60=best) at 24 months of corrected age

Secondary

MeasureTime frameDescription
Failure rate of implementation of the early support program in speech-language pathology or early drop-out.at 24 months of corrected ageEarly drop-out is defined by 3 or less sessions.
Score in the Ages & Stages Questionnaires communication domain at 12 and 18 months of corrected age.at 12 and 18 months of corrected age.The Ages \& Stages Questionnaires is a parental questionnaire that is strongly correlated with traditional developmental tests. The Ages \& Stages Questionnaires communication domain takes into account receptive and expressive language, includes 6 questions, and ranges from 0 (worst) to 60 (best).
score at Inventaire Français du Développement Communicatif questionnaire at 12, 18 and 24 months of corrected ageat 12, 18 and 24 months of corrected ageThe IFDC questionnaire is a recommended tool for monitoring and early detection of language deficits. It is expressed as a percentile (0=worst, 100=best).
Score at Communication and Symbolic Behavior Scales questionnaire at 12 and 24 months of corrected ageat 12 and 24 months of corrected ageThe Communication and Symbolic Behavior Scales qestionnaire is a tool for screening for communication disorders and interactions. It ranges from 0 (worst) tro 57 (best).

Countries

France

Contacts

STUDY_DIRECTORMichèle Granier, MD

Centre Hospitalier Sud Francilien

PRINCIPAL_INVESTIGATORVéronique Zupan-Simunek, MD

Hôpital Antoine Béclère

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 27, 2026